References
- European Medicines Agency. Notification of a referral under Article 107i of Directive 2001/83/EC [Internet]. 2013 Feb 28 [cited 2017 Sep 28]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Procedure_started/WC500139756.pdf
- European Medicines Agency: EMA/404308/2013. Assessment report for flupirtine containing medicinal products [Internet]. 2013 Jun 24 [cited 2017 Sep 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500146103.pdf
- Teva Gmbh, Germany. Summary of Product Characteristics: Flupirtine [Internet]. 2015 [cited 2017 Sep 28]. Available from: http://mri.cts-mrp.eu/download/DE_H_3430_001_FinalSPC_2of2.pdf
- Kaplan S, Ehlken B, Hamann X. The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany. Curr Med Res Opin. 2019, 35(1), 33–40.
- European Medicines Agency (EMA). Withdrawal of pain medicine flupirtine endorsed [Internet]. 2018 Mar 23 [cited 2018 Jun 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-31/Position_provided_by_CMDh/WC500248611.pdf
- Richter H, Dombrowski S, Hamer H, et al. Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci. 2015;13:Doc14.
- European Medicines Agency. Scientific conclusions and grounds for variation to the terms of the marketing authorisations subject to conditions and detailed explanation for the differences from the PRAC recommendation: Annex II;2013 [Internet] [cited 2018 Aug 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Position_provided_by_CMDh/WC500146106.pdf
- PROTECT consortium. The pharmacoepidemiological research on outcomes of therapeutics by a European Consortium (PROTECT) objectives of PROTECT [Internet] [cited 2019 Jan 24]. Available from: http://www.imi-protect.eu/objectives.shtml
- Puljak L. Prescribers’ compliance is part of benefit–risk assessment of medicines and it can lead to failure of risk minimization measures and withdrawals of medicines. Curr Med Res Opin. 2019;35(1):5–6.
- Kruik-Kolloffel WJ, van der Palen J, Kruik HJ, et al. Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel – proton pump inhibitor interaction. Pharmacol Res Perspect. 2016;4:e00242.
- Mosis G, Stijnen T, Castellsague J, et al. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2006;55:537–542.
- Piening S, Haaijer-Ruskamp FM, de Vries JT, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 2012;35:373–385.
- Piening S, Reber KC, Wieringa JE, et al. Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. Clin Pharmacol Ther. 2012;91:838–845.
- Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193–198.